Spectacles improve night driving in presbyopes

Article

Spectacle correction improves distance vision during night-time driving in presbyopes but has a negative impact on near vision.

Spectacle correction improves distance vision during night-time driving in presbyopes but has a negative impact on near vision, according to a recent study published in Investigative Ophthalmology & Visual Science.

The research team, led by Dr Byoung Sun Chu of Queensland University of Technology, Brisbane, Australia, examined 11 presbyopes who had only previously used reading spectacles as a correction method. Repeated measurements were taken at night-time on a closed-road circuit while each subject wore four different types of power matched vision corrections in a randomized order. The corrective methods used were single-vision distance lenses (SV), progressive addition spectacle lenses (PAL), monovision contact lenses (MV) and multifocal contact lenses (MTF CL).

Each patient's ability to detect and avoid low-contrast road hazards, recognition of road signs and near targets and legibility distance of street signs was measured. Additionally, the ability for the study group to keep within their lanes and the overall driving time were measured along with eye movement data (fixation duration and number of fixations).

It was concluded that presbyopic correction worn by naive wearers affected night-time driving ability with PAL and SV giving the best results for distance tasks but SV correction negatively affected the near dashboard viewing targets. It was also shown that MTF CL gave the shortest legibility distance for street signs and the longest fixation times.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.